Table 2.
Changes in immunosuppressive therapy (IST) use during the open-label extension.
| Type of/reason for change in IST use | IST change events, n (%)aN = 719 | Patients, n (%)bN = 117 |
|---|---|---|
| Change in IST use | 719 (100.0) | 90 (76.9) |
| Decrease in daily dose of 1 IST | 386 (53.7) | 74 (63.2) |
| Increase in daily dose of 1 IST | 158 (22.0) | 51 (43.6) |
| Stoppage of an existing IST | 101 (14.0) | 51 (43.6) |
| Start a new IST | 69 (9.6) | 37 (31.6) |
| Increase in daily dose of >1 IST | 3 (0.4) | 3 (2.6) |
| Decrease in daily dose of >1 IST | 2 (0.3) | 2 (1.7) |
| Stoppage or decrease in dose of ≥1 IST | 489 (68.0) | 84 (71.8) |
| MG symptoms improved | 280 (38.9) | 57 (48.7) |
| MG symptoms worsened | 3 (0.4) | 3 (2.6) |
| New indication other than MG for IST use | 13 (1.8) | 7 (6.0) |
| Side effects—intolerant to existing IST | 49 (6.8) | 18 (15.4) |
| Otherc | 144 (20.0) | 47 (40.2) |
| Start or increase in dose of ≥1 ISTd | 230 (32.0) | 71 (60.7) |
| MG symptoms worsened | 111 (15.4) | 44 (37.6) |
| New indication other than MG for IST use | 19 (2.6) | 12 (10.3) |
| Otherc | 98 (13.6) | 43 (36.8) |
a
Percentage of all changes in IST use.
b
Any given patient may have experienced multiple changes under the same or different categories.
c
“Other” category largely used to describe temporary dosing/treatment changes in response to conditions such as asthma/chronic obstructive pulmonary disease, conjunctivitis, and urinary tract infections, or to support surgery.
d
Two reasons in this category were problematic (not applicable values).
MG, myasthenia gravis.